Abstract
In this issue of Blood, Schewe and colleagues identify a novel Fc-engineered CD19 antibody with significant activity in a xenograft model of patient-derived mixed lineage leukemia (MLL)–rearranged acute lymphoblastic leukemia (ALL).1
Cite
CITATION STYLE
APA
Advani, A. S. (2017, September 28). “MOR” engineering of antibodies in ALL. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-07-797126
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free